Timolol 0.1% gel (nyogel 0.1%®) once daily versus conventional timolol 0.5% solution twice daily: A comparison of efficacy and safety

Ophthalmologica

Volumn 216, Issue 6, 2002, Pages 449-454

  Rouland, Jean François ^a   Morel Mandrino, Patricia ^b   Elena, Pierre Paul ^b   Polzer, Heinz ^c   Sunder Raj, Palaniswamy ^d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CLIROPHTHA   (France)

^c MEDproject Pharma   (United Kingdom)

^d Delta House   (United Kingdom)

Author keywords

Intraocular pressure; Ocular hypertension; Primary open angle glaucoma; Timolol gel; Timolol solution

Indexed keywords

ANTIGLAUCOMA AGENT; TIMOLOL;

ADULT; AGED; ARTICLE; BRONCHITIS; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUTION; DRUG TOLERABILITY; GEL; HEADACHE; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 0036960501     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067548     Document Type: Article

References (19)

1. Van Buskirk EM, Fraunfelder FT: Ocular beta-blockers and systemic effects. Am J Ophthalmol 1984;98:623-624.
2. Fraunfelder FT, Meyer SM: Systemic side effects from ophthalmic timolol and their prevention. J Ocul Pharmacol 1987;3:177-184.
3. Akingbehin AO, Raj PS: Ophthalmic topical beta-blockers: Review of ocular and systemic adverse effects. J Toxicol Cut Ocular Toxicol 1990;9:131-147.
4. van Buskirk EM: The compliance factor. Am J Ophthalmol 1986;101:609-610.
5. Kass MA, Gordon M, Morley RE, et al: Compliance with topical timolol treatment. Am J Ophthalmol 1987;103:188-193.
6. Greenberg RN: Overview of patient compliance with medication dosing: A literature review. Clin Ther 1984;6:592-599.
7. Lee DA, Fechtner RD, Fiscella RG, Singh K, Stewart WC: Emerging perspectives on glaucoma: Highlights of a roundtable discussion. Am J Ophthalmol 2000;130:S1-S11.
8. Elena PP, Polzer H, Khosravi E: Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol) and a novel gel vehicle (T-Gel). Invest Ophthalmol Vis Sci 1993;34(S):1490.
9. Mayer H, von der Ohe N: Efficacy of a novel hydrogel formulation in human volunteers. Ophthalmologica 1996;210:101-103.
10. Otto SR, Hoeh HR: Efficacy and ocular tolerance of timolol gel 0.1% once daily versus timolol 0.25% aqueous eye drops twice daily. Invest Ophthalmol Vis Sci 1997;38(S):826.
11. Hoeh HR, Schnarr KD, Baeumner D: Innovative low-dose timolol eye gel: Greater safety and improved compliance in the treatment of primary chronic open angle glaucoma and ocular hypertension. Augenspiegel 1999;10:24-31.
12. Ardjomand N, Ardjomand N, Komericki P: Efficacy of timolol hydrogel 0.1% in patients with primary open angle glaucoma and ocular hypertension. Spektrum Augenheilkd 2000;14:203-208.
13. Ardjomand N, Komericki P: Timolol maleate hydrogel 0.1% - a prospective multi-center study. Spektrum Augenheilkd 2001;15:9-13.
14. Levobunolol Study Group. Levobunolol: A four year study of efficacy and safety in glaucoma treatment. Ophthalmology 1989;96:642-645.
15. Silverstone DE, Arkfeld D, Cowan G, Lue JC, Novack GD: Long term diurnal control of intraocular pressure with levobunolol and with timolol. Glaucoma 1985;7:138-140.
16. Laurence J, Holder D, Vogel R, et al: A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J Glaucoma 1993;2:177-182.
17. Shedden AH: Timolol maleate in a gel forming solution: A novel formulation of timolol maleate. Chibret Int J Ophthalmol 1994;10:32-36.
18. Uusitalo H, Kahonen M, Ropo A, Turjanmaa V: Evaluation of efficacy and systemic side effects of topical 0.1% timolol gel and 0.5% aqueous timolol maleate. abstracts of the XII Congress of the European Society of Ophthalmology, Stockholm, 1999; abstract SP353, p 182.
19. Hayreh SS, Podhajsky P, Zimmerman MB: Beta-blocker eye drops and nocturnal arterial hypotension. Am J Ophthalmol 1999;128:301-309.